Allurion Technologies, Inc. (ALUR) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of a loss of $1.53 per share. This compares to earnings of $2.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 128.10%. A quarter ago, it was expected that this company would post a loss of $5 per share when it actually produced a loss of $7, delivering a surprise of -40%.Over the last four quarters, t ...

Silicon Laboratories (SLAB) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.92 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this chipmaker would post a loss of $0.11 per share when it actually produced a loss of $0.11, delivering no surprise.Over the last four quarters, the company has surpassed ...

NLight (LASR) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.18. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 77.78%. A quarter ago, it was expected that this laser maker would post a loss of $0.21 per share when it actually produced a loss of $0.30, delivering a surprise of -42.86%.Over the last four quarters, the company has surpassed co ...

Central Garden (CENT) came out with quarterly earnings of $1.04 per share, beating the Zacks Consensus Estimate of $0.94 per share. This compares to earnings of $0.99 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 10.64%. A quarter ago, it was expected that this maker of products for the pet supply and lawn and garden markets would post a loss of $0.03 per share when it actually produced earnings of $0.21, delivering a surpri ...

Core Viewpoint - Hims & Hers Health, Inc. reported strong quarterly earnings, exceeding expectations and showing significant year-over-year growth in both earnings and revenues [1][2]. Financial Performance - The company reported earnings of $0.20 per share, surpassing the Zacks Consensus Estimate of $0.12 per share, and up from $0.05 per share a year ago, representing an earnings surprise of 66.67% [1]. - Revenues for the quarter ended March 2025 were $586.01 million, exceeding the Zacks Consensus Estimate by 8.91%, and significantly higher than the $278.17 million reported in the same quarter last year [2]. Stock Performance - Hims & Hers Health shares have increased approximately 68.8% since the beginning of the year, contrasting with a decline of 3.3% in the S&P 500 [3]. - The stock currently holds a Zacks Rank 2 (Buy), indicating expectations for it to outperform the market in the near future [6]. Future Outlook - The current consensus EPS estimate for the upcoming quarter is $0.15 on revenues of $562.21 million, and for the current fiscal year, it is $0.64 on revenues of $2.33 billion [7]. - The industry outlook is favorable, with the Medical Info Systems sector ranking in the top 28% of Zacks industries, suggesting strong potential for stock performance [8].

Core Viewpoint - Huntsman reported a quarterly loss of $0.11 per share, aligning with the Zacks Consensus Estimate, but this reflects a deterioration from a loss of $0.06 per share a year ago [1] - The company’s revenues for the quarter were $1.41 billion, missing the Zacks Consensus Estimate by 4.68% and down from $1.47 billion year-over-year [2] Financial Performance - Huntsman has surpassed consensus EPS estimates two times over the last four quarters, but has only topped consensus revenue estimates once [2] - The company experienced a significant surprise in the previous quarter, with an expected loss of $0.12 per share turning into an actual loss of $0.25, resulting in a surprise of -108.33% [1] Stock Performance - Huntsman shares have declined approximately 26.2% since the beginning of the year, contrasting with the S&P 500's decline of -5.3% [3] - The current Zacks Rank for Huntsman is 5 (Strong Sell), indicating expectations of underperformance in the near future [6] Earnings Outlook - The consensus EPS estimate for the upcoming quarter is $0.04 on revenues of $1.62 billion, while the estimate for the current fiscal year is -$0.05 on revenues of $6.21 billion [7] - The trend for earnings estimate revisions for Huntsman is currently unfavorable, which may impact future stock movements [6] Industry Context - The Chemical - Diversified industry, to which Huntsman belongs, is currently ranked in the bottom 16% of over 250 Zacks industries, suggesting a challenging environment [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, emphasizing the importance of monitoring these changes [5]

Core Insights - Tarsus Pharmaceuticals reported a quarterly loss of $0.64 per share, which is better than the Zacks Consensus Estimate of a loss of $0.69, and an improvement from a loss of $1.01 per share a year ago, indicating a 36.6% year-over-year improvement [1] - The company achieved revenues of $78.34 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 8.06% and showing a significant increase from $27.61 million in the same quarter last year [2] - Tarsus Pharmaceuticals has consistently surpassed consensus EPS estimates over the last four quarters, indicating strong performance relative to market expectations [2] Financial Performance - The company has shown an earnings surprise of 7.25% for the recent quarter and an 11.76% surprise in the previous quarter, reflecting positive momentum in earnings performance [1][2] - The current consensus EPS estimate for the upcoming quarter is -$0.38, with expected revenues of $86.76 million, while the estimate for the current fiscal year is -$1.22 on revenues of $361.17 million [7] Market Position - Tarsus Pharmaceuticals shares have underperformed the market with a decline of about 6.3% since the beginning of the year, compared to a decline of 5.3% for the S&P 500 [3] - The company holds a Zacks Rank 2 (Buy), indicating expectations for the stock to outperform the market in the near future based on favorable estimate revisions [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Tarsus Pharmaceuticals belongs, is currently ranked in the top 32% of over 250 Zacks industries, suggesting a favorable industry outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Group 1: Earnings Performance - TPG RE Finance Trust reported quarterly earnings of $0.24 per share, missing the Zacks Consensus Estimate of $0.26 per share, and down from $0.30 per share a year ago, representing an earnings surprise of -7.69% [1] - The company posted revenues of $37.03 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 0.56%, and down from $38.93 million year-over-year [2] - Over the last four quarters, TPG RE Finance Trust has not surpassed consensus EPS estimates and has topped consensus revenue estimates only once [2] Group 2: Stock Performance and Outlook - TPG RE Finance Trust shares have declined approximately 12.8% since the beginning of the year, compared to a -6% decline in the S&P 500 [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $0.25 on revenues of $37.52 million, and for the current fiscal year, it is $1.03 on revenues of $149.72 million [7] Group 3: Industry Context - The Real Estate - Operations industry, to which TPG RE Finance Trust belongs, is currently ranked in the bottom 34% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact TPG RE Finance Trust's stock performance [5][6]

CG Oncology, Inc. (CGON) shares ended the last trading session 25% higher at $27.97. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 15.3% loss over the past four weeks.CG Oncology’s shares jumped 25% on Monday after the company unveiled exceptionally durable best-in-disease phase III data for its bladder cancer candidate, cretostimogene grenadenorepvec, at the American Urological Association meeting. In the BOND-0 ...

Check Point Software (CHKP) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.19 per share. This compares to earnings of $2.04 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.91%. A quarter ago, it was expected that this data security company would post earnings of $2.66 per share when it actually produced earnings of $2.70, delivering a surprise of 1.50%.Over the last four quart ...